NCT03746067View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 21, 2015

Primary Completion Date

January 13, 2016

Study Completion Date

January 13, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

TS-134

5 mg, 10 mg, or 20 mg oral solution

DRUG

Placebo

Matched Placebo oral solution

Trial Locations (1)

91206

PAREXEL - Early Phase Clinical Unit-Los Angeles, Glendale

All Listed Sponsors
lead

Taisho Pharmaceutical R&D Inc.

INDUSTRY

NCT03746067 - Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers | Biotech Hunter | Biotech Hunter